Skip to main content


Out of control—or delivering value?

Pharma innovation isn’t free—but few believe the sick should bear the costs. Balancing costs and benefits requires data, collaboration, and the courage to try new things.

Efficacy within reach

Is affordability a pipe dream?

As drugs become more sophisticated and targeted, they often become dramatically more expensive. Even common drugs can see massive price increases when patents change hands or new uses are found.

As our healthcare systems and patients bear the cost of pharmaceuticals, how do we create a system that is fair to all—especially those whose lives could be saved by greater availability of medications?

Read the article
Read the article

Controlling Rx costs: Top 5 reasons for a PBM RFP

Five reasons why RFPs with PBMs should be a regular practice to help control Rx costs.

Read the article

Impact of the Inflation Reduction Act on plans seeking creditable coverage

The Inflation Reduction Act’s higher standards for retiree prescription drug plans may require plan sponsors to enrich benefits in 2025 for creditable coverage.

Read the article
White paper

Average Manufacturer Price cap removal: Implications for state Medicaid programs

As a new federal law, effective in 2024, removes a cap on manufacturers' drug rebate amounts, we explore the implications for state Medicaid programs.

Read the article

Payer strategies for GLP-1 medications for weight loss

We examine various strategies related to GLP-1 medications such as Wegovy when used for weight loss to help payers understand the landscape, develop a coverage strategy, and minimize waste.
Read the article

NADAC-plus: An emerging paradigm in pharmacy pricing

LWith increased consumer and regulatory scrutiny on drug prices, stakeholders in the pharmacy supply chain are exploring drug pricing alternatives.

Download PDF

Medicare Part D risk and claim cost changes with the Inflation Reduction Act

The Medicare Part D program is on the verge of massive change due to passage of the Inflation Reduction Act.

Read the article

An end to manufacturer rebates as we know them today?

What do Part D plan sponsors need to consider when rebates cease to exist?

Read the article

A new Part D benefit design?

Prescription Drug Pricing Reduction Act proposes major changes to Part D

Read the article

Related Milliman products

Healthcare analytics
Procurement management

Milliman Payer Network Check

Make high-quality financial comparisons of provider medical reimbursement rates across large insurance carriers.

Pharmaceutical claims analysis
Pharmaceutical claims analytics


Compare contracted discount rates and savings with real-time pharmaceutical claims experience reporting.

ACA compliance and affordability
ACA compliance & affordability

Healthcare Reform Dashboard

Give small and mid-size employers essential analysis needed for ensuring compliance and plan affordability under the Affordable Care Act (ACA).

Healthcare analytics
Healthcare analytics


Adopt the healthcare industry’s leading platform for data warehousing and healthcare analytics.

ACA utilization and cost evaluation
Medicare plan selection solution

Medicare Suggest

Deliver detailed, personalized Medicare plan price comparisons through a simple, web or API experience.

Premium comparison platform
Cost-saving analysis

Milliman Specialty Pharmacy Insights

Identify opportunities to manage specialty pharmacy costs for existing and new drug therapies.


Related Milliman services

Product development and pricing: Healthcare

Medicare Part D

Pharmacy benefits consulting

We’re here to help

Ask the tough questions. We’re ready for them.

We’re here to help

Ask the tough questions. We’re ready for them.

popup image